Vetr cut shares of Endo International (NASDAQ:ENDP) (TSE:ENL) from a strong-buy rating to a buy rating in a research note released on Monday. Vetr currently has $8.92 target price on the stock.

Several other brokerages also recently issued reports on ENDP. Goldman Sachs Group started coverage on shares of Endo International in a report on Thursday, September 28th. They set a sell rating and a $7.00 price target for the company. Royal Bank of Canada cut their price target on shares of Endo International from $9.00 to $8.00 and set a sector perform rating for the company in a report on Friday, November 10th. Guggenheim started coverage on shares of Endo International in a report on Tuesday, December 12th. They set a neutral rating and a $8.50 price target for the company. Cantor Fitzgerald cut their price target on shares of Endo International from $9.00 to $7.00 and set a neutral rating for the company in a report on Friday, November 10th. Finally, Piper Jaffray Companies reaffirmed a hold rating and issued a $9.00 target price on shares of Endo International in a research note on Sunday, September 17th. Two analysts have rated the stock with a sell rating, sixteen have given a hold rating and six have assigned a buy rating to the company. The stock presently has an average rating of Hold and an average price target of $11.34.

Endo International (NASDAQ ENDP) opened at $8.28 on Monday. Endo International has a 1-year low of $5.77 and a 1-year high of $17.99. The stock has a market cap of $1,786.51, a PE ratio of 1.65, a P/E/G ratio of 2.18 and a beta of 0.59. The company has a current ratio of 1.08, a quick ratio of 0.86 and a debt-to-equity ratio of 10.78.

Endo International (NASDAQ:ENDP) (TSE:ENL) last announced its quarterly earnings results on Thursday, November 9th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $0.06. Endo International had a negative net margin of 126.97% and a positive return on equity of 66.98%. The firm had revenue of $786.90 million during the quarter, compared to the consensus estimate of $794.93 million. During the same period last year, the firm posted $1.01 EPS. The firm’s quarterly revenue was down 11.0% on a year-over-year basis. equities analysts predict that Endo International will post 3.67 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Arizona State Retirement System raised its stake in shares of Endo International by 1.5% during the second quarter. Arizona State Retirement System now owns 83,700 shares of the company’s stock worth $935,000 after buying an additional 1,200 shares during the last quarter. Point View Wealth Management Inc. raised its stake in shares of Endo International by 16.6% during the second quarter. Point View Wealth Management Inc. now owns 13,331 shares of the company’s stock worth $149,000 after buying an additional 1,900 shares during the last quarter. Comerica Bank raised its stake in shares of Endo International by 1.2% during the second quarter. Comerica Bank now owns 155,786 shares of the company’s stock worth $1,818,000 after buying an additional 1,905 shares during the last quarter. Gamco Investors INC. ET AL grew its holdings in Endo International by 5.6% during the second quarter. Gamco Investors INC. ET AL now owns 62,700 shares of the company’s stock valued at $700,000 after purchasing an additional 3,300 shares during the period. Finally, Riverhead Capital Management LLC grew its holdings in Endo International by 64.4% during the second quarter. Riverhead Capital Management LLC now owns 15,025 shares of the company’s stock valued at $168,000 after purchasing an additional 5,887 shares during the period. 93.06% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Endo International (ENDP) Downgraded to “Buy” at Vetr” was first posted by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://www.watchlistnews.com/endo-international-endp-downgraded-to-buy-at-vetr/1772621.html.

About Endo International

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Analyst Recommendations for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.